Tirzepatide
Category: |
GLP-1 Analogs |
SKU: |
{{ds.variantSkuVal}} |
Price: |
{{ds.variantPriceVal}} |
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
Tirzepatide
Tirzepatide is a synthetic peptide originally developed in the context of type 2 diabetes research. It acts as a dual agonist of both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual activity has made it a subject of great scientific interest in metabolic and obesity-related studies.
In comparative studies, tirzepatide has been compared with other incretin-based compounds. The results indicate that it produced greater body weight reductions than single-agonist compounds, such as semaglutide, although over a longer observation period than emerging multi-agonists, such as retatrutide.
Mechanism of Action (Investigational)
GLP-1 Pathway: Its role in appetite regulation and satiety signaling has been studied.
GIP pathway: Its role in insulin release, hypothalamic signaling, and overall energy balance has been investigated.
Research Results
Scientific studies have examined tirzepatide in areas such as:
Body weight modulation: Some trials reported average reductions of approximately 24% after 72 weeks of observation.
Appetite and cravings: Its influence on energy intake and satiety has been investigated.
Metabolic activity: Its relationship with fat oxidation and energy expenditure has been studied.
Glucose regulation: Its impact on insulin sensitivity and blood glucose markers has been extensively investigated.
(30-day supply kit)